ZBP1 and COVID-19: Interestingly, a recent study reported the effects of GSK’872 treatment in mice expressing human ACE2 in the nasal and lung epithelium infected with the SARS-CoV-2 viruses to inhibit the ZBP-1 branch of PANoptosis in a mouse model of COVID-19 (135).